# LGX818 for Patients With BRAFV600 Mutated Tumors

> **NCT01981187** · PHASE2 · TERMINATED · sponsor: **Pfizer** · enrollment: 12 (actual)

## Conditions studied

- Solid Tumor
- Hematologic Malignancies

## Interventions

- **DRUG:** LGX818

## Key facts

- **NCT ID:** NCT01981187
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-01-14
- **Primary completion:** 2015-09-01
- **Final completion:** 2015-10-13
- **Target enrollment:** 12 (ACTUAL)
- **Why stopped:** Due to slow enrollment and lack of response observed during the enrollment period, the Sponsor decided to close study enrollment early on 28 January 2015
- **Last updated:** 2021-03-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01981187

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01981187, "LGX818 for Patients With BRAFV600 Mutated Tumors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01981187. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*